Pascal Soriot

Soriot cautions that biology and disease are too complex, so claims that AI will cure cancer are overstated.

If we remain active in the industry long enough, we quickly learn to be humble. Diseases are complicated, biology is complicated. Claiming that AI will cure cancer may be going a little too far,

Soriot said 20 upcoming high-value trial readouts could create over $20 billion in peak annual revenue, with a significant part materializing in coming years.

Over the next year, 20 “high-value trial readouts” could, if positive, yield peak annual revenue opportunities surpassing $20 billion. “A significant part” of that total should “become reality over the next few years,” Soriot proclaimed.

Soriot said embedding AI more deeply lets AstraZeneca grow without adding as much headcount, making the company faster and smarter.

AI is helping "make us faster, smarter," Soriot said. AstraZeneca can "grow without growing," meaning it can "grow without adding as many people as you would have if you didn't have the use of AI."

Soriot said AstraZeneca's pipeline momentum and 20 upcoming high-value readouts could deliver over $20 billion in peak revenue, with a significant part materializing in coming years.

Since February, the company has reported positive results from 12 late-stage programs and brought four new drugs to market, CEO Pascal Soriot told analysts. Over the next year, 20 "high-value trial readouts" could, if positive, yield peak annual revenue opportunities surpassing $20 billion. "A significant part" of that total should "become reality over the next few years," Soriot proclaimed.

Soriot says combining Tagrisso with Orpathys can broaden first-line use and extend treatment duration, shielding the franchise from new competitors.

The combination with Orpathys has the potential to drive both broader first-line use as well as longer Tagrisso-based treatment duration, keeping patients on Tagrisso rather than switching them off and therefore, protecting the franchise from newcomers.

Soriot believes ADCs will be the treatment backbone across tumors and the Summit deal enables flexible combinations with next-gen IO partners.

We believe ADCs will become the backbone of treatment across tumor types, and this partnership gives flexibility to combine them with the optimal next-generation immuno-oncology partner for each setting.

Soriot says 2027 brings over 20 key readouts representing more than $20 billion in non-risk-adjusted peak sales potential.

We expect more than 20 high-value trial readouts and pivotal data for 9 potential new medicines. If you look at the whole list of readouts on this slide, and of course, not everything is going to work, you have in nonrisk-adjusted peak year revenue more than $20 billion.

Soriot says the roughly 60% average risk adjustment in forecasts is conservative, supporting confidence in growth beyond 2030.

our risk adjustment across the totality of the portfolio, about 60%. So it's not very ambitious. We've done much better than that in the past. So that's what also gives me confidence.

Soriot declines to quantify a post-2030 target for now, but says pipeline strength underpins confidence in growth beyond 2030.

I think it's a little bit too early, to be honest. The -- and I'll explain why in a second, the reason why we are confident of growing post 2030 is the strength of the pipeline we have in our hands.

Soriot sees China's biopharma rise as both tailwind and headwind, more tailwind for firms that collaborate and learn to compete with Chinese companies.

it's both a headwind -- a tailwind and a headwind, of course, because these companies are very competitive. But I think it's overall more of a tailwind than a headwind for the companies that will be able to collaborate with Chinese companies, but also learn to compete with them.

Soriot explains MFN requires GDP-adjusted parity, with US prices drifting down slightly and European prices up over time, and he is cautiously optimistic about Japan and Europe.

MFN doesn't require Japan or Europe to reach U.S. prices, it requires that it reaches GDP-adjusted U.S. prices. And again, the logic of the MFN program is over time that U.S. prices would decline a little bit and European prices would go up a little bit.

Soriot frames AstraZeneca's weight-management push as treating metabolic syndrome and visceral fat via combinations, an underappreciated opportunity.

What we're trying to do is address the metabolic syndrome, the insulin resistance. And there are a lot of people around the world, millions, hundreds of millions who don't look obese, they may not even sometimes look overweight, but they have abdominal adiposity, the visceral fat.

Soriot says the restructuring program redeploys resources, with every dollar saved reinvested in the pipeline, and AI lets the company grow without adding as many people.

we believe we have to redeploy resources. We believe we have a pipeline we need to support. And then every dollar we can save, we reinvest in the pipeline.

Soriot said moving focus from patent-expiring drugs to oncology and rare diseases could make some R&D roles redundant.

Soriot said shifting focus from patent-expiring drugs such as Farxiga and Brilinta to oncology and rare diseases could render some R&D roles redundant.

Soriot says AstraZeneca's late-stage pipeline and transformative technologies put it on track for its 2030 ambition, with 2027 readouts worth over $20 billion in potential.

We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars. With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade.

Soriot says AstraZeneca is on track to meet its 2030 ambition and sustain growth into the next decade, backed by late-stage blockbuster candidates and scaling technologies.

With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition and to sustain growth through the next decade

Soriot said AstraZeneca's R&D team has done substantial mRNA work and the company believes it can make a contribution in cancer vaccines, with more to be disclosed in coming months and years.

Our R&D team has done a lot of work in the last couple of years on mRNA technology. We believe we can actually do something in the field, and you'll hear more about this in the months and years to come,

Soriot says the AstraZeneca-Oracle collaboration unites healthcare and AI leaders at global scale.

This unique collaboration brings leaders in healthcare and AI together at a global scale.

Soriot said the AstraZeneca-Oracle AI partnership can help clinicians find patients earlier, optimize trials and continuously generate evidence across a medicine's lifecycle.

We can help clinicians identify patients sooner, optimize clinical trials, and generate evidence continuously across the lifecycle of a medicine,

Soriot says combining AstraZeneca's science with Oracle's data and technology can help find patients sooner, optimise trials and generate evidence continuously across a medicine's lifecycle.

Combining AstraZeneca’s world-class science with Oracle’s deep data and technology expertise, we can help clinicians identify patients sooner, optimise clinical trials, and generate evidence continuously across the lifecycle of a medicine,

Pascal Soriot said AstraZeneca performed strongly in the first half and remains on track to hit its $80 billion total revenue target by 2030.

In the first half, we performed strongly and remain on track to achieve our total revenue target of $80 billion by 2030.

Original (zh)

上半年，我们表现强劲，仍有望在2030年实现800亿美元的总营收目标。

Soriot says Kendall Square is a leading innovation hub and a key location for AstraZeneca's next-generation discoveries, underpinning its $1B+ Massachusetts R&D investment.

Kendall Square is a leading innovation ecosystem, and it is one of the key locations where AstraZeneca will discover the next generation of scientific breakthroughs,